Strategic Alliances

Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.

Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

Tevogen’s lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients who are unable to take or unlikely to benefit from currently available preventative or therapeutic options, as well as a subset of patients suffering from long COVID.

• No dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome
• Correction of lymphopenia, reduction of inflammatory markers and viral load
• Trial patients were infected by Delta and a wide range of Omicron variants

We believe the perspective and expertise afforded by strategic collaborations to be fundamental in successful introduction of our lead product TVGN-489.

For collaboration inquiries please contact sadiq.khan@tevogen.com

Corporate Executive Summary

Accessible Immunotherapies and Business Excellence Through Innovative Science

Corporate Overview

Purpose, Innovations, and Opportunity to Join Before Tevogen’s Next Growth Spurt

February 10th, 2023
Kindly fill out the form below to download the presentation.